Articles On Actinogen Medical (ASX:ACW)

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

Plus, Actinogen receives approval of its application for a UK Innovation Passport as part of the Innovative Licensing and Access Pathway (ILAP) for Xanamem in the treatment of Alzheimer’s disease Enrolment in XanaCIDD phase 2a trial of c...

Actinogen Medical (ASX: ACW) has treated the first subject in its clinical trial of patients with biomarker-positive mild to moderate Alzheimer’s disease. The XanaMIA Phase 2b trial involves 220 participants with elevated levels of the bloo...

Atomo announces more purchase orders for HIV Self-Tests Actinogen says first patient was treated in Alzheimer’s disease study Imugene has opened enrolment for expansion study in solid tumours   Atomo sells more HIV self-test kits Atomo Di...

Nyrada jumped 400pc in a single day last month The company reported good results from its Brain Injury Program Could Nyrada be the next Neuren?   Nyrada’s 400% share price rally on February 28 was the biggest single day jump of any ASX st...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Research reports on ASX-listed companies, to download in full. **** -Actinogen Medical ((ACW)) by Edison Research: https://www.fnarena.com/index.php/download-article/?n=17DBBDB4-E20C-03AC-A84AF5C456D084E9 -Amaero International ((3DA)) by Re...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

One in eight people in the world have some form of mental disorder TrivarX’s AI technology diagnoses mental health via sleep monitoring Stockhead reached out to TrivarX’s COO, Kai Sun   Mental health has always been a big global issue, bu...

  Local markets ride commodities lift to offset weak performance from Wall Street on Friday ASX 200 benchmark finished the day on +0.09pc, a lot higher than it really had any right to Resources led the way, overcoming a significant deadwei...

The ASX benchmark has closed slightly lower on Friday Losses across the Energy Sector weighed Small caps led ID8   The Aussie sharemarket has ended lower on Friday, driven to a small disgrace by the ongoing declines in oil prices – down...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, that made announcements today.   ICYMI Leade...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

The ASX has ended -0.4% lower, just 2.5 points from 2023 parity Utilities only sector in green Small caps led by 4DX, Infinity and a few Lake Johnston lithium plays   The local market is back to digging its little hole from which it may t...

Research reports on ASX-listed companies, to download in full. **** -Actinogen Medical ((ACW)) by Research as a Service (RaaS): https://www.fnarena.com/index.php/download-article/?n=2B537F21-A3D7-CB04-98294578CBAE8E12 -Amaero International ...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

Xanamem® is an oral, brain-penetrant tissue cortisol synthesis inhibitor that has shown promising safety and clinical activity in three placebo-controlled trials and has the potential to treat a variety of neurodegenerative and neuropsyc...

Benchmark ASX index finishes +1% higher ASX Sectors led by Utilities (+4.2%) and all ended higher on the day Funny bunch of small cap winners including MOB, CZR, NGL   The ASX200 doesn’t seem to mind a bit of war on Tuesday, rising very...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

Highlights Changes to the XanaMIA protocol reduce cost by AUD 30 million over the next two years and speed time to initial results while preserving the 36-week design and trial endpoints. UK sites added to the XanaCIDD trial of cognitiv...

On Tuesday, the Australian stock market experienced a decline primarily due to a sell-off in technology and real estate stocks. This drop is part of a broader trend where investors are adjusting their portfolios in anticipation of an extend...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

US FDA requested Botanix to change its instructions paper Antisense says ATL1102 could be effective in muscular dystrophy Actinogen changes Phase 2b design to reduce cost and time to initial results   Botanix plunges after receiving FDA f...

The ASX opened lower by 0.4% on Tuesday, reflecting market adjustments in anticipation of prolonged higher interest rates. At noon, the S&P/ASX 200 is 0.49 per cent lower at 7,042.10, primarily driven by losses in property and tech sect...

  Lake Resources (ASX:LKE) has announced a successful completion of the lithium carbonate test program, which is an important milestone towards the completion of DFS. In response,Lake CEO David Dickson said, “most DLE lithium carbonate anno...

26 Sep 2023 - A snapshot of the stocks on the move, featuring Lake Resources (ASX:LKE), Talon Energy (ASX:TPD) and Actinogen Medical (ASX:ACW).

Research reports on ASX-listed companies, to download in full. **** –Actinogen Medical ((ACW)) by Edison Research: https://www.fnarena.com/index.php/download-article/?n=7D2FBF3D-0297-B05B-8F498AF62BD096F8 –AFT Pharmaceuticals ((AFP)) by Edi...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

The company said the funds raised will be used to progress its Phase 2 clinical trial program, including completion of the XanaCIDD trial of Xanamem in patients with cognitive impairment associated with depression.

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Neuren’s US FDA approval for trofinetide has seen its share price boosted ~130% in past year   Eye disease specialist Opthea is undertaking two Phase 3 trials to treat Wet AMD with results due in mid 2024 Anteris Technologies is developing...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

ASX health stocks fall 2.4% in the past five days in line with broader markets Mesoblast crashes more than 50% after US FDA rejects a key product  ImpediMed falls after calls for board spill with discontent following cap raise Healthcare...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

The ASX 200 has had its worst day in roughly a month with a 1.29 percentage dip  The sectors were a shade of spilt claret, with Utilities and Real Estate leading losses Standout small caps: BCAL Diagnostics and American West Metals   Loca...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

The ASX was higher by around 2.5% in July The best sectors were Tech and Energy We look at the best and worst performing ASX stocks for the month For the month of July, most major indexes on the ASX rose by around 2.5%. Name % Change...

Actinogen Medical's (ASX:ACW) chief medical officer, Dr Dana Hilt, has presented an academic poster to the Alzheimer’s Association International Conference in Amsterdam.

Research reports on ASX-listed companies, to download in full. **** –Actinogen Medical ((ACW)) by Edison Research: https://www.fnarena.com/index.php/download-article/?n=628D02C0-B9D8-EA23-2DB35CB4E58A7CBE –AFT Pharmaceuticals ((AFT)) by Edi...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

Xanamem® is an oral, brain-penetrant tissue cortisol synthesis inhibitor that has shown promising safety and clinical activity in three placebo-controlled trials and has the potential to treat a variety of neurodegenerative and neuropsyc...

Research reports on ASX-listed companies, to download in full. –Actinogen Medical ((ACW)) by Edison Research: https://www.fnarena.com/index.php/download-article/?n=F863639F-EF2C-E5CB-37099553DD439B58 –AFT Pharmaceuticals ((AFP)) by Edison R...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...